Literature DB >> 11499755

Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model.

K Wang1, Z Zhou, X Zhou, K Tarakji, E J Topol, A M Lincoff.   

Abstract

OBJECTIVES: The role of P-selectin in the process of restenosis was evaluated using a recombinant immunoglobulin (Ig) chimera form of its ligand, soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig), as a competitive inhibitor for the natural ligand on leukocytes.
BACKGROUND: Inflammation and coagulation activation after vascular injury may be an important factor in the development of restenosis. P-selectin has been shown to mediate leukocyte-endothelium and leukocyte-platelet interaction. These interactions are mediated through binding of P-selectin to P-selectin glycoprotein ligand-1 (PSGL-1) located on the surface of leukocytes.
METHODS: Balloon injury was induced in the left anterior descending and right coronary arteries of 16 pigs at a balloon/artery diameter ratio of 1.5:1. Either rPSGL-Ig (1 mg/kg) or saline was randomly administered 15 min before balloon injury as an intravenous bolus. Four weeks after injury, morphometric analysis, immunohistochemistry and histological evaluation were performed on injured arterial segments.
RESULTS: Increased luminal area was found in the rPSGL-Ig group compared with the placebo group (1.63 +/- 0.57 mm2 vs. 1.26 +/- 0.32 mm2, p = 0.044) owing to significantly reduced neointimal hyperplasia (cross-sectional area, 0.46 +/- 0.45 mm2 vs. 0.13 +/- 0.11 mm2, p = 0.013). Immunohistochemistry and histological evaluation showed a significant decrease in the presence of tumor necrosis factor-alpha, interleukin-1 beta, and infiltration of macrophages in the injured vessel segments in the rPSGL-Ig group.
CONCLUSIONS: P-selectin antagonism using rPSGL-Ig decreases neointimal hyperplasia following balloon injury, by inhibiting the inflammatory and thrombotic responses at the site of balloon injury, which appears to play a pivotal role in the pathogenesis of restenosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11499755     DOI: 10.1016/s0735-1097(01)01347-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Recombinant P-selectin glycoprotein-ligand-1 delays thrombin-induced platelet aggregation: a new role for P-selectin in early aggregation.

Authors:  Jean-François Théorêt; Wissam Chahrour; Daniel Yacoub; Yahye Merhi
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

2.  Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo.

Authors:  N M Valenzuela; L Hong; X-Da Shen; F Gao; S H Young; E Rozengurt; J W Kupiec-Weglinski; M C Fishbein; E F Reed
Journal:  Am J Transplant       Date:  2012-12-27       Impact factor: 8.086

Review 3.  Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses.

Authors:  Jesse W Rowley; Aloke V Finn; Patricia A French; Lisa K Jennings; Danny Bluestein; Peter L Gross; Jane E Freedman; Steven R Steinhubl; Guy A Zimmerman; Richard C Becker; Harold L Dauerman; Susan S Smyth
Journal:  Circ Cardiovasc Interv       Date:  2012-04       Impact factor: 6.546

Review 4.  Novel uses for anti-platelet agents as anti-inflammatory drugs.

Authors:  S C Pitchford
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

5.  P-Selectin Targeted Dexamethasone-Loaded Lipid Nanoemulsions: A Novel Therapy to Reduce Vascular Inflammation.

Authors:  Viorel Simion; Cristina Ana Constantinescu; Daniela Stan; Mariana Deleanu; Monica Madalina Tucureanu; Elena Butoi; Ileana Manduteanu; Maya Simionescu; Manuela Calin
Journal:  Mediators Inflamm       Date:  2016-09-14       Impact factor: 4.711

Review 6.  Failure to Launch: Targeting Inflammation in Acute Coronary Syndromes.

Authors:  Jennifer A Rymer; L Kristin Newby
Journal:  JACC Basic Transl Sci       Date:  2017-08-28

Review 7.  Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies.

Authors:  Li Li; Sainan Liu; Jianying Tan; Lai Wei; Dimeng Wu; Shuai Gao; Yajun Weng; Junying Chen
Journal:  J Tissue Eng       Date:  2022-03-24       Impact factor: 7.813

8.  Integrin α9 regulates smooth muscle cell phenotype switching and vascular remodeling.

Authors:  Manish Jain; Rishabh Dev; Prakash Doddapattar; Shigeyuki Kon; Nirav Dhanesha; Anil K Chauhan
Journal:  JCI Insight       Date:  2021-05-24

9.  Core2 1-6-N-glucosaminyltransferase-I deficiency protects injured arteries from neointima formation in ApoE-deficient mice.

Authors:  Huan Wang; Weiyu Zhang; Rong Tang; Robert P Hebbel; M Anna Kowalska; Chunxiang Zhang; Jamey D Marth; Minoru Fukuda; Chuhong Zhu; Yuqing Huo
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-04-16       Impact factor: 8.311

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.